NR1H3 and myeloid sarcoma: The identification of ten patients diagnosed with MS harboring a rare NCOA3 p.Arg485Cys substitution capable of enhancing the expression of pro-inflammatory mediators, together with a suggestive association between MS and NCOA3, and significant associations with NCOA1, NCOA5, NR1D1 and NR1H3 [6, 9], suggests an important role for nuclear receptor co-activators, and the LXR and PPAR pathways, in the pathophysiology of MS.